Background and intent

The 2010 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis (RA) were developed to identify patients who fulfill a consistent, evidence-based definition of RA for clinical research, registries, and trials. They replaced older 1987 ACR criteria to improve sensitivity in early disease and to incorporate serologic and acute-phase data alongside joint counts.

The instrument is explicitly framed as classification, not a standalone diagnostic checklist. In practice, clinicians still integrate history, examination, imaging, differential diagnosis, and treatment response. The score summarizes how closely a patient’s presentation aligns with the RA phenotype the criteria were designed to capture.

Who the criteria apply to: entry conditions

Before any points are counted, the patient should meet two entry requirements:

• Definite clinical synovitis (swelling or fluid) in at least one joint on examination. Imaging evidence of synovitis may support but does not by itself replace thoughtful clinical assessment.
• Synovitis is not better explained by another condition (for example, other inflammatory arthritides, crystal disease, mechanical or degenerative problems, infection, or other systemic rheumatic diagnoses in the individual context).

If these conditions are not reasonably met, a high or low score should not be over-interpreted—the tool was validated and intended for patients in whom inflammatory joint disease is already the working problem.

Structure of the score

Four domains contribute points, for a maximum of 10:

• Joint involvement (0–5 points)
• Serology—rheumatoid factor (RF) and/or anti–citrullinated protein antibody (ACPA), often reported as anti-CCP (0–3 points)
• Acute-phase reactants—C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR) (0–1 point)
• Duration of symptoms (0–1 point)

A total score of 6 or greater is the threshold for fulfilling the 2010 ACR/EULAR classification definition of RA, when entry criteria are satisfied.

Domain 1: Joint involvement

Points reflect the pattern and extent of affected joints. The criteria distinguish large and small joints and use progressively higher scores as more small joints are involved or as the total burden crosses predefined cutoffs.

Large joints

For this instrument, large joints are the shoulders, elbows, hips, knees, and ankles (bilaterally counted as separate joints when involved).

Small joints

Small joints include the metacarpophalangeal (MCP), proximal interphalangeal (PIP), second through fifth metatarsophalangeal (MTP), thumb interphalangeal, and wrist joints. The original publication excludes distal interphalangeal (DIP) joints, the first carpometacarpal joint, and the first MTP joint from the small-joint count.

Scoring categories (joint domain)

Select the single row that best matches the patient’s joint involvement at the time of assessment:

• 0 points: One large joint involved.
• 1 point: Two to ten large joints involved (and not meeting a higher small-joint category).
• 2 points: One to three small joints involved, with or without large joint involvement.
• 3 points: Four to ten small joints involved, with or without large joint involvement.
• 5 points: More than ten joints involved, with at least one small joint involved.

Counting should follow the same rules consistently across visits when the score is used longitudinally (for example, in cohort documentation). Uncertainty in borderline swelling versus soft-tissue changes can shift the joint domain; clinical judgment and, when appropriate, imaging may help.

Domain 2: Serology (RF and/or anti-CCP)

Serologic points depend on whether RF and/or ACPA (anti-CCP) are negative, low-positive, or high-positive relative to the upper limit of normal (ULN) of the local laboratory assay. Assays and ULNs vary by platform and institution, so the same numeric titre may fall into different categories in different labs.

• 0 points: Negative RF and negative anti-CCP (both at or below the ULN).
• 2 points: Low-positive RF or low-positive anti-CCP—above the ULN but less than or equal to three times the ULN (≤3× ULN).
• 3 points: High-positive RF or high-positive anti-CCP—greater than three times the ULN (>3× ULN).

When both RF and anti-CCP are available, the serology category is determined by the higher of the two result categories (the more abnormal classification governs). If only one test is available, that result defines the serology domain, understanding that missing data can underestimate risk of fulfilling criteria.

Seronegative RA remains well recognized clinically; such patients may accumulate fewer points in this domain even when inflammation and erosive disease are present.

Domain 3: Acute-phase reactants

This domain captures systemic inflammatory activity often associated with active RA, while acknowledging that many conditions can elevate CRP or ESR.

• 0 points: CRP and ESR are both in the normal range per local laboratory standards.
• 1 point: Abnormal CRP and/or abnormal ESR.

If only one marker is measured, use the available data cautiously: a normal omitted test does not automatically imply both are normal unless that is clinically true.

Domain 4: Duration of symptoms

Symptom duration refers to the patient’s complaint period attributable to the inflammatory arthritis process under evaluation, not necessarily the first day of any musculoskeletal symptom ever.

• 0 points: Symptoms present for fewer than six weeks.
• 1 point: Symptoms present for six weeks or longer.

Very early presentations may score lower here despite eventual evolution toward classic RA; repeat assessment over time is often informative.

Interpreting the total score

After summing the four domains, compare the total to the prespecified cutoff:

• Total ≥ 6: Fulfills the 2010 ACR/EULAR classification criteria for RA, provided the entry criteria (definite synovitis, no better alternative explanation) are met.
• Total < 6: Does not fulfill the classification definition by this scoring system. That does not exclude inflammatory arthritis, early RA, or need for therapy—especially in seronegative or minimally elevated acute-phase states.

The score is most useful when documented transparently (joint pattern, serology multiples of ULN, which labs, symptom duration) so that peers can reproduce the classification decision.

Clinical and research use

Common uses include trial enrollment, registry consistency, epidemiologic case definition, and teaching. In day-to-day care, many treatment decisions rest on function, prognosis, comorbidity, and shared goals rather than on the classification score alone.

The criteria perform best when applied to populations resembling those in the derivation and validation work—adults with undifferentiated or early inflammatory arthritis in whom RA is a leading hypothesis. Special situations (very early disease, palindromic patterns, predominant tenosynovitis, PMR overlap features, postpartum onset, infection mimics) require extra diagnostic care.

Limitations and practical caveats

• Classification is not diagnosis: The score supports standardized labeling; it does not replace integrative clinical reasoning.
• Assay dependence: ULN-based serology categories require local reference ranges and method awareness.
• Joint counting variability: Interobserver differences in swelling detection can change the joint domain.
• Acute-phase nonspecificity: Elevated CRP or ESR may reflect infection, malignancy, or other inflammatory states.
• Seronegative disease: Lower serology points can prevent reaching the threshold despite clinically convincing RA.